171 related articles for article (PubMed ID: 9365198)
1. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
2. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
4. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Lønning PE; Ekse D
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):409-12. PubMed ID: 8541238
[TBL] [Abstract][Full Text] [Related]
5. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
7. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Geisler J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):245-53. PubMed ID: 14623518
[TBL] [Abstract][Full Text] [Related]
10. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Geisler J; Lien EA; Ekse D; Lønning PE
J Steroid Biochem Mol Biol; 1997; 63(1-3):53-8. PubMed ID: 9449206
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17beta-estradiol and estrone 3-sulfate in human plasma.
Hosogi J; Tanaka H; Fujita K; Kuwabara T; Ikegawa S; Kobayashi N; Mano N; Goto J
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(2):222-7. PubMed ID: 19700374
[TBL] [Abstract][Full Text] [Related]
12. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.
Pasqualini JR; Chetrite G; Blacker C; Feinstein MC; Delalonde L; Talbi M; Maloche C
J Clin Endocrinol Metab; 1996 Apr; 81(4):1460-4. PubMed ID: 8636351
[TBL] [Abstract][Full Text] [Related]
13. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Santen RJ; Demers L; Ohorodnik S; Settlage J; Langecker P; Blanchett D; Goss PE; Wang S
Steroids; 2007 Jul; 72(8):666-71. PubMed ID: 17588628
[TBL] [Abstract][Full Text] [Related]
14. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
Friedrichs K; Jänicke F
Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
[TBL] [Abstract][Full Text] [Related]
15. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
16. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
18. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
19. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]